ClinicalTrials.gg
Not yet recruitingNCT07742280Updated Aug 3, 2026

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Brexpiprazole for Extended-Release Injection in Subjects With Schizophrenia

A Phase 2/3 interventional study of Brexpiprazole for ER injection, 45 mg and Brexpiprazole for ER injection, 100 mg in Schizophrenia, sponsored by Bostal Drug Delivery Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Bostal Drug Delivery Co., Ltd · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is to evaluate the pharmacokinetics (PK), safety and tolerability of Brexpiprazole, administered subcutaneously, in subjects with schizophrenia.

02

Conditions studied

  • Schizophrenia

Browse trials for

03

In context

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

This study's planned enrollment of 16 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

Bostal Drug Delivery Co., Ltd is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects and/or subject's legally acceptable representative (LAR) is able to sign and subject is willing to comply with the trial protocol and to attend the clinic visits.
  2. Male or female subjects diagnosed with schizophrenia as per , Fifth Edition, Text Revision (DSM-5-TR) (or later) criteria.
  3. Subjects with a Clinical Global Impression-Severity of Illness (CGI-S) Score of ≤ 4 at screening and on enrolment prior to IP dosing (Day -1).
  4. Subjects with Positive and Negative syndrome-scale (PANSS) total score ≤75 at screening and on enrolment prior to IP dosing (Day -1).
  5. Subjects aged 18-65 years (both inclusive) having (BMI) between 18.50 to 30.00 kg/m2
  6. Schizophrenic subjects who are clinically stable on their current antipsychotic medication other than Brexpiprazole, for a duration of at least 8 weeks prior to screening. [Refer to Appendix A for List of Allowable medications] NOTE: Subjects must NOT be taking > 2 antipsychotic medications for their disease
  7. Subjects who have tolerated oral Brexpiprazole prior to dosing.
  8. Subjects with acceptable haematology status:

    • ≥ 9 g/dL
    • (ANC) ≥ 1500 cells/μL
    • count ≥ 100,000 cells/μL
    • White blood cell count (WBC) ≥ 4000 cells/μL
  9. Subjects with acceptable liver function:

    • (ALT) ≤ 2 X (ULN)
    • Aspartate aminotransferase (AST) ≤ 2 X ULN
    • \< 1.5 X ULN
    • Alkaline phosphatase ≤ 2 X ULN
  10. Subjects with ≥ 60 mL/minute (using the Cockcroft- Gault Equation).
  11. Female subjects of with negative pregnancy test at screening and at enrolment day, and agree to practice acceptable methods of during the study.

    Acceptable methods of contraception are:

    • Oral or other (e.g. injection, patch or implant) hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication
    • Intrauterine device (IUD) or intrauterine system (IUS)
    • Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)
    • Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 6 weeks prior to study participation
  12. Subjects who agree to avoid drinking alcohol during the study.
  13. Subjects with accessible vein access from arm.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known to Brexpiprazole or related class of drugs or to any of the of the formulation.
  2. Subjects currently in acute, manic episodes of schizophrenia, as assessed by the Investigator.
  3. Subjects with history of or a current diagnosis of concurrent mental disorder besides schizophrenia (e.g., schizoaffective-disorder, major depressive disorder, bipolar I disorder, bipolar II disorder, general anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, dementia or mild neurocognitive disorder, and personality disorder).
  4. Subjects who have any suicidal ideation based on history, routine psychiatric status examination, investigator's judgment, or who have an answer of "yes" on any of the questions of 'Suicidal Ideation' on the CSSRS for screening. [Refer to Appendix B]
  5. Subjects with history or presence of neuroleptic malignant syndrome (NMS), tardive dyskinesia, Parkinson's disease, epilepsy or other seizure disorders, cognitive and motor impairment, pathological gambling, dysphagia or other compulsive behaviour
  6. Subjects with a prior personal or family history of dystonic reactions to medications.
  7. Subjects with dyslipidemia.
  8. Subjects with a history of syncope or a presence of significant orthostatic hypotension (i.e., a drop in systolic blood pressure of 20 mm Hg or more and/or a drop in diastolic blood pressure of 10 mm Hg or more within 3 minutes of standing from a minimum of 5 minutes in supine position) at screening.
  9. Subjects with known history or presence of any systemic disease (e.g., cardiovascular disease, cerebrovascular disease, diabetes mellitus, etc.)
  10. Subject who are on concurrent treatment with other anti-psychotic Longacting Injection (LAIs).
  11. Subject who has received concomitant medications that are strong inhibitors, CYP2D6 inhibitors, or CYP3A4 inducers within 14 days prior to study drug administration (or within five half-lives since the last drug administration, whichever is greater), or is expected to require such treatment during the study.
  12. Subjects with any other medical condition or serious inter-current illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness other than schizophrenia /social situations that would limit adherence to study requirements.
  13. Any other condition(s) which could significantly interfere with protocol compliance
  14. Subjects found positive for urine screen for drugs of abuse (except for benzodiazepine, which is a permissible medication if supported by prescription)
  15. Subjects with major surgical procedure (including periodontal) within 28 days of IP dosing or plan to have major surgical procedure during the study
  16. Subjects with current surgical or other non-healing wounds.
  17. Subjects who have participated in any clinical trial with another drug or other investigational intervention within 90 days of enrolment.
  18. Loss of ≥ 350 mL (1 unit) of blood within 90 days before enrolment in the study.
  19. Subjects with history of difficulty with donating blood or difficulty in accessibility of veins.
  20. Subjects with positive serology for surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Virus (HCV), or (HIV).

    Note: Subjects with Hepatitis B core antibody (HBcAb) positive result can be enrolled if a confirmatory negative test is obtained suggestive of no active infection currently.

  21. Alcoholics (alcohol consumption of more than 14 units per week for men and more than 7 units per week for women, each unit equivalent to 360 mL of beer or 150 mL of wine or 45 mL of spirits with 40% alcohol content) or those who have a positive urine alcohol test
  22. Subjects who have consumed tobacco-containing products (smoking, tobacco chewing, etc.), xanthine containing food, poppy seeds, and beverages (chocolates, tea, coffee, or cola drinks) or alcohol within 48.00 hours (02 days) prior to receiving the first dose of oral Brexpiprazole tablets for the tolerability assessment period (on Day -44) and within 48.00 hours (02 days) prior to IP dosing (on Day 1) or subject who is not ready to abstain from them till the last PK sample collection for oral Brexpiprazole tablets (on Day -27) and till 30 days after the IP administration on Day 1.
  23. Subjects who have consumed grapefruit or its juice and cranberry juice within 96.00 hours (04 days) prior to dosing or subject who is not ready to abstain from them till last study-related procedure.
  24. Subjects currently smoking greater than or equal to 10 cigarettes or equivalent per day.
  25. Pregnant or lactating women
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Brexpiprazole for ER injection, 45 mg

    Drug: Brexpiprazole for ER injection, 45 mg

  • Experimental
    Brexpiprazole for ER injection, 100 mg

    Drug: Brexpiprazole for ER injection, 100 mg

Interventions

  • DrugBrexpiprazole for ER injection, 45 mg

    Single-dose, Subcutaneous

  • DrugBrexpiprazole for ER injection, 100 mg

    Single-dose, Subcutaneous

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum peak plasma concentration

    Time frame: Pre-dose to 190 days post-dose

  2. Clast

    Last measurable plasma concentration

    Time frame: Pre-dose to 190 days post-dose

  3. Tmax

    Time of occurence of Cmax

    Time frame: Pre-dose to 190 days post-dose

  4. AUC0-last

    Area under curve from time zero to last measurable concentration

    Time frame: Pre-dose to 190 days post-dose

  5. Kel

    Time frame: Pre-dose to 190 days post-dose

  6. T1/2

    Half-life

    Time frame: Pre-dose to 190 days post-dose

  7. Vd/F

    Volume of distribution

    Time frame: Pre-dose to 190 days post-dose

  8. CL/F

    Apparent clearance of drug from plasma

    Time frame: Pre-dose to 190 days post-dose

  9. MRT

    Mean residence time of the drug in the body

    Time frame: Pre-dose to 190 days post-dose

  10. AUC_%Extrap_obs

    Percentage of AUC due to extrapolation from Tlast to infinity

    Time frame: Pre-dose to 190 days post-dose

  11. AEs

    Adverse events

    Time frame: Day 1 to Day 190

  12. SAEs

    Serious AEs

    Time frame: Day 1 to Day 190

  13. Change from baseline in physical examination findings

    Change from baseline in clinical physical examination findings will be assessed descriptively for safety monitoring. The assessment includes general appearance, skin, head, ears, eyes, nose and throat, chest and lungs, cardiovascular, abdomen, musculoskeletal and extremities, neurological, psychiatric, and mental status examinations. Individual findings will be evaluated for clinically meaningful changes from baseline.

    Time frame: Day 1 to Day 190

  14. Blood Pressure

    Evaluate the clinical significance of test value outside of the reference range.

    Time frame: Day 1 to Day 190

  15. Orthostatic hypotension

    Drop in blood pressure due to a change in body position from standing to supine

    Time frame: Day 1 to Day 190

  16. Columbia-Suicide Severity Rating Scale (C-SSRS) assessment

    Change in suicidality from baseline.

    Time frame: Day 1 to Day 190

  17. Clinical Laboratory Tests

    Evaluate the clinical significance of each test value outside of the reference range. Lab tests including blood test for Human immunodeficiency virus (HIV), Hepatitis B virus (HBsAg and HBcAb) and Hepatitis C virus (HCV), haematology (Total WBC count, total RBC count, hemoglobin, HCT (PCV), lymphocytes, monocytes, granulocytes, platelet count, and ANC), biochemistry (Fasting blood glucose, BUN, serum creatinine, creatinine clearance, total bilirubin, SGPT, SGOT, ALP, serum cholesterol, sodium, calcium, potassium, chloride, magnesium, LDL, HDL and TG), serum pregnancy test (only for females of childbearing potential) and urine test

    Time frame: Day 1 to Day 190

  18. 12-lead ECG Assessment

    For safety assessment. ECG findings will be evaluated descriptively based on the overall interpretation (Normal, Abnormal Not Clinically Significant \[NCS\], or Abnormal Clinically Significant \[CS\]).

    Time frame: Day 1 to Day 190

  19. Pulse Rate

    Evaluate the clinical significance of test value outside of the reference range.

    Time frame: Day 1 to Day 190

  20. Respiratory Rate

    Evaluate the clinical significance of test value outside of the reference range.

    Time frame: Day 1 to Day 190

  21. Body Temperature

    Evaluate the clinical significance of test value outside of the reference range.

    Time frame: Day 1 to Day 190

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Aug 3, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07742280
Lead sponsor
Bostal Drug Delivery Co., Ltd
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 3, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion